Technological advances in the serological diagnosis of Chagas disease in dogs and cats: a systematic review

Natália Erdens Maron Freitas¹, Fernanda Lopes Habib¹, Emily Ferreira Santos¹, Ângelo Antônio Oliveira Silva¹, Natália Dantas Fontes¹, Leonardo Maia Leony¹, Daniel Dias Sampaio², Marcio Cerqueira de Almeida³, Filipe Dantas-Torres⁴ and Fred Luciano Neves Santos¹,⁵*

Abstract

Background: Chagas disease (CD) is caused by Trypanosoma cruzi, which is transmitted mainly through the feces/urine of infected triatomine bugs. The acute phase lasts 2–3 months and is characterized by high parasitemia and nonspecific symptoms, whereas the lifelong chronic phase features symptoms affecting the heart and/or digestive tract occurring in 30–40% of infected individuals. As in humans, cardiac abnormalities are observed in T. cruzi-infected dogs and cats. We reviewed the technological advances in the serological diagnosis of CD in dogs and cats.

Methods: A review of the published literature during the last 54 years (1968–2022) on the epidemiology, clinical features, diagnosis, treatment and prevention of CD in dogs and cats was conducted.

Results: Using predefined eligibility criteria for a search of the published literature, we retrieved and screened 436 publications. Of these, 84 original studies were considered for inclusion in this review. Dogs and cats are considered as sentinels, potentially indicating an active T. cruzi transmission and thus the risk for human infection. Although dogs and cats are reputed to be important for maintaining the T. cruzi domestic transmission cycle, there are no commercial tests to detect past or active infections in these animals. Most published research on CD in dogs and cats have used in-house serological tests prepared with native and/or full-length recombinant antigens, resulting in variable diagnostic performance. In recent years, chimeric antigens have been used to improve the diagnosis of chronic CD in humans with encouraging results. Some of them have high performance values (> 95%) and extremely low cross-reactivity rates for Leishmania spp., especially the antigens IBMP-8.1 to IBMP-8.4. The diagnostic performance of IBMP antigens was also investigated in dogs, showing high diagnostic performance with negligible cross-reactivity with anti-Leishmania infantum antibodies.

Conclusions: The development of a commercial immunodiagnostic tool to identify past or active T. cruzi infections in dogs and cats is urgently needed. The use of chimeric recombinant T. cruzi antigens may help to fill this gap and is discussed in this review.

Keywords: Trypanosoma cruzi, Dogs, Cats, Diagnosis, Serology, Epidemiology

*Correspondence: fred.santos@fiocruz.br

¹ Advanced Health Public Laboratory, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Waldemar Falcão Street, 121, Candeal, Bahia, Salvador 40296-710, Brazil
Full list of author information is available at the end of the article

Background

Chagas disease (CD) or American trypanosomiasis is a neglected parasitic disease caused by the hemoflagellate protozoan Trypanosoma cruzi. Recent estimates indicate that 6–7 million people are infected worldwide, with
10,000 deaths attributable to CD annually in 21 Latin American countries [1]. Due to the continuous presence of the vector, 70 million people in this region are at risk of contracting the disease via vector transmission [1]. The parasite is primarily transmitted through the feces or urine of infected bloodsucking triatomine bugs also referred to as kissing bugs (Hemiptera: Reduviidae) [1]. Over 130 triatomine species have been identified as potential vectors of \textit{T. cruzi} [2]. Fifty-two triatomine species have been described in Brazil, of which five are considered of epidemiological importance because of their domestic habitats: \textit{Triatoma infestans} (Fig. 1A), \textit{Panstrongylus megistus} (Fig. 1B, C), \textit{Triatoma brasiliensis}, \textit{Triatoma pseudomaculata} and \textit{Triatoma sordida} (Fig. 1D, E, F). Non-vectorial routes of transmission are also important for \textit{T. cruzi} transmission, such as blood transfusion or the use of blood products, congenital transmission, consumption of contaminated food and beverages, organ donation and laboratory accidents [3].

Increased travel and migration flows have facilitated the spread of \textit{T. cruzi}-infected individuals, making the disease a global health problem, particularly in non-endemic countries in Europe, North America, Asia and Oceania [4–7].

Clinically, human CD is divided into two phases: acute and chronic. The acute phase begins within 1–2 weeks of infection, lasts 2–3 months and is characterized by high parasitemia and nonspecific symptoms such as fever, tachycardia and lymphadenopathy [8]. The lifelong chronic phase can occur in two forms: an indeterminate form, which is usually a latency period in which individuals show no symptoms but have positive serological results, and a symptomatic form. Approximately 30–40% of chronically infected individuals progress to a symptomatic form, which can be further subdivided into cardiac, digestive, or mixed forms (cardiac and digestive) [8]. As in humans, cardiac disease is also observed in \textit{T. cruzi}-infected dogs [9–11] and cats [12]. Indeed, some animals

![Fig. 1](image-url) Triatomines normally found in endemic areas of South America. Preserved pair of \textit{Triatoma infestans} A and \textit{Panstrongylus megistus} B, kindly provided by Dr. Gilmar Jose da Silva Ribeiro Júnior (Fiocruz-Bahia). C shows a live \textit{Panstrongylus megistus} female captured in the city of Barra do Mendes, Bahia, Brazil. Live triatomines of the species \textit{Triatoma sordida} found on the floor D and roof E of a chicken house in the rural area of the municipality of Tremedal, Bahia. F shows some T. sordida adult specimens captured for gut content analysis.
develop progressive chronic myocarditis with cardiac dilatation and electrocardiogram abnormalities that may lead to sudden death. Clinical signs may include splenomegaly, lymphadenopathy and heart failure [13].

Although CD was discovered more than a century ago, this zoonosis still poses a public health threat [14]. The presence of domestic animals in the environment is a risk factor for human infection because they may attract triatomines to human dwellings. Indeed, triatomines typically feed on chickens, pigs, dogs and cats [15, 16]. Figure 2 shows a typical scenario in poor rural communities in Latin American countries where mud houses are still common (Fig. 2A, E, F) and domestic animals such as dogs, chickens and pigs are present (Fig. 2B, C, D respectively). Among domestic animals, dogs and cats play an important role in maintaining the domestic cycle of *T. cruzi*, since these animals are susceptible to different forms of infection [17, 18]. They are reputed to be the main reservoirs of *T. cruzi* in Latin America and some regions of the US [13, 19–21]. Dogs and cats are also considered as sentinels for human infection [22, 23], since they can indicate the presence of an active *T. cruzi* transmission cycle and thus the risk of human infection.

Despite the public health and veterinary importance, there are no commercially available tests to detect past or active *T. cruzi* infections in dogs and cats. In this review, we summarize basic information on CD in dogs and cats, with particular emphasis on diagnostic methods.

**Search strategy, eligibility and review**

An online search was performed in the US National Library of Medicine National Institutes of Health (PubMed, Bethesda MD, USA; https://pubmed.ncbi.nlm.nih.gov/), the Latin American and Caribbean Health Science Literature Database (LILACS; https://lilacs.bvsalud.org/) and the Scientific Electronic Library Online (Scielo Brazil, São Paulo SP—Brazil; https://scielo.br/) databases using Health Sciences Descriptors (DeCS). The descriptors in the different databases were “Chagas disease,” “dogs,” and “cats” in Portuguese, English and Spanish. The Boolean operator “AND” was used to cross descriptors and keywords. Search results were then filtered for the period 1968 to 2022 and extracted into a database in Microsoft Excel (Microsoft Corp., Redmond, WA, USA) in CSV format (comma-separated values).

Inclusion criteria were (1) articles indexed in the previously cited databases; (2) original studies in Portuguese, Spanish, or English; (3) published between 1968 and 2022. The survey took place from January to June 2022, excluding secondary publications such as books, monographs, dissertations and theses.

The extraction and analysis of primary data were conducted by two independent researchers. Exclusion of articles was based first on reading the titles as the first analysis, followed by reading the abstracts (if available) and finally reading the full texts. In case of doubts or discrepancies, a third researcher was consulted. A total of 436 articles were found during the initial search. After an initial analysis of the titles, 191 articles were excluded, and another 86 articles were not included because they were duplicates. Of the remaining 159 articles, the abstracts were read and 106 were considered for conducting the integrative review. Of these, 17 articles were excluded because they were not available in the scientific literature. After the qualitative analysis, 84 of the 89 selected articles were considered for conducting this review. The process of study selection was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Additional file 1: PRISMA) model [24], which is shown in Fig. 3.

*Trypanosoma cruzi* infection and CD in dogs

Dogs become infected after coming into contact with the feces of triatomine bugs containing *T. cruzi* trypomastigote (Fig. 4), by ingesting infected triatomines, or congenitally [25]. They are considered the most important domestic reservoirs of *T. cruzi* in areas where CD is endemic owing to their proximity to humans, high parasitemia in acute phase of the disease and propensity to attract triatomines [17, 20, 22]. Nonetheless, the role of dogs as reservoirs may apparently vary. For instance, a study conducted in Brazil showed that dogs from some regions presented negative blood cultures and fresh blood preparations [26], whereas studies conducted in Argentina [22, 27] and Brazil [28] indicated that vast majority of seropositive dogs had active parasitemia.

A study conducted in 1996 estimated that dogs contribute 13.9 times more than humans to triatomine infection in households [29]. Accordingly, the likelihood of a triatomine bug to become infected by *T. cruzi* was found 50 times higher after a single blood meal on a dog than on a human [29]. In another study examining the feeding habits of over 1000 domestic *T. infestans*, it was found that dogs were the most common blood source (49%), followed by cats (39%), humans (38%) and chickens (29%) [17].

Considering the role of dogs as reservoirs for *T. cruzi*, the seroprevalence in dogs has also been used in mathematical models for domestic transmission of human CD [30]. However, seroprevalence data from different countries may vary widely (Fig. 5), which may be partly attributed to the variability in terms of transmission risk, but also to sample size and serological tests used by different research groups to detect anti-*T. cruzi* antibodies in dogs, as well as to the genetic variability of the circulating *T. cruzi* strains (discrete typing units.
Fig. 2 The epidemiologic scenario of poor rural communities in many Latin American countries. Mud house with cracks where triatomines can hide (A–C), with detail of a crack in a rural adobe/brick house (A). B Inside of the house illustrated in (A). Mud house with cracks (C) with presence of domestic animals in the environment: dog (D), chickens (E) and pigs (F). These animals can attract triatomines for a blood meal, thus helping maintain the peridomestic cycle of *T. cruzi*. Photographs were taken in rural areas of the municipalities of Tremedal (A and B) and Irecê, Bahia, Brazil (E–F).
In Mexico, a study conducted in 2010 reported a prevalence of 34% [31], while another study carried out in 2017 detected a prevalence of 4.4% [32]. Other studies conducted in Mexico have reported different prevalence values [33–43]. Recently, anti-\(T. cruzi\) antibodies were detected in 50% (17/34) of dogs from two rural settlements in the Sierra de Los Tuxtlas, Veracruz, Mexico [44]. In Costa Rica, 5.2–27.7% of dogs were seropositive in endemic areas [45–47], whereas in Colombia the prevalence ranged from 9.6% to 34% [48–52]. In the US, a study with 86 working dogs reported a seroprevalence of 14.1% [53], whereas other studies reported a lower prevalence [54–57]. \(Trypanosoma cruzi\) infection was reported in 63 (16.8%) of 375 dogs from a teaching
hospital in Texas [58] and in 110 (18.1%) of 608 dogs in shelters across this same state [59]. In 2020, an American nationwide study using dog samples from 41 states and Washington DC revealed a seropositivity in 120/1610 animals (7.5%) [60]. In a National Park located along the Texas-Mexico border, 28.6% (4/14) of dogs were reactive on at least two serologic assays [61]. More recently, 26 of 197 (13.2%) shelter dogs from Oklahoma had detectable antibodies against *T. cruzi* [62]. In Brazil, the seroprevalence in dogs ranged from 0 to 53%, according to research conducted in different regions [63–83]. In other Latin American countries, the seroprevalence varies according to geographic setting, e.g. 1.9% in Peru [84], 4.3% in Grenada [85], 5.2% in French Guiana [86], 10% in Nicaragua [87], 4.6–19.9% in Chile [88–90], 11.1–17.6% in Panama [91, 92], 6.4–22.1% in Venezuela [93–96], 17.5–53% in Argentina [17, 97–99], 22% in Bolivia [100] and 57.1% in Ecuador [101].

Regarding predisposing factors, it has been observed that dogs with poor nutritional conditions are 6.3 times more likely to be infected compared to well-nourished dogs in the same endemic area [102]. This is thought to be related to a deficient innate immune response in dogs with poor nutritional conditions, which favors the occurrence of higher parasitemia [102]. Another predisposing factor is keeping dogs in kennels with multiple dogs. In fact, an American study found that the risk of *T. cruzi* infection in dogs living in kennels is 30.7% per year [103].

During the acute phase of infection, *T. cruzi* circulates in the bloodstream and trypomastigotes can be observed in most tissues, triggering a systemic inflammatory response with the production of proinflammatory cytokines (Fig. 6).

Clinical signs vary widely according to infection phase (acute versus chronic) and to dog’s age. For instance, the main presenting clinical signs in young puppies are lethargy, generalized lymphadenopathy, slow capillary refill time with pale mucous membranes and in some cases splenomegaly and hepatomegaly [13]. On the other hand, if infection occurs after 6 months of age, dogs may display no signs of acute disease other than slight depression and low-rising parasitemia [13]. In general, the main lesion in young dogs experimentally infected with *T. cruzi* is acute myocarditis that begins in the atria and spreads through the interventricular septum toward the ventricles [104]. When fully developed, it is located predominantly in the right atrium, the right half of the ventricular septum and the free wall of the right ventricle. Electrocardiogram (ECG) changes are progressive and reflect atrial involvement. Heart block occurs only in the terminal stage and

---

**Fig. 4** Developmental stages of *Trypanosoma cruzi* in invertebrate (triatomine bug) and vertebrate (dog, cat and human) hosts.
### Seroprevalence of Chagas disease in dogs and cats in different endemic countries of North, Central and South America

#### Brazil

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Acre                      | 8.7            |      |      |
| Bahia                     | 0.7            |      |      |
| Bahia                     | 0.5            |      |      |
| Bahia                     | 17.6           |      |      |
| Bahia                     | 21.9           |      |      |
| Bahia                     | 36.0           |      |      |
| Bahia                     | 13.3           |      |      |
| Bahia                     | 13.0           |      |      |
| Bahia                     | 53.0           |      |      |
| Minas Gerais              | 29.4           |      |      |
| Pará                       | 36.2           |      |      |
| Pará                       | 0.0            |      |      |
| Pará                       | 4.1            |      |      |
| Pará                       | 7.9            |      |      |
| Pará                       | 0.0            |      |      |
| Pará                       | 7.6            |      |      |
| Pará                       | 7.7            |      |      |
| Pará                       | 11.0           |      |      |
| Pará                       | 42.5           |      |      |
| Pará                       | 9.4            |      |      |
| Pará                       | 10.1           |      |      |
| Pará                       | 4.6            |      |      |

#### Argentina

| Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------|----------------|------|------|
| Santiago del Estero | 46.0           |      |      |
| Entre Ríos          | 55.0           |      |      |
| Chaco               | 17.5           |      |      |
| Santiago del Estero | 33.8           |      |      |

#### Chile

| Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------|----------------|------|------|
| Tarapacá            | 10.3           |      |      |
| Tarapacá            | 10.0           |      |      |
| Tarapacá            | 4.6            |      |      |

#### Bolivia

| Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------|----------------|------|------|
| Chuquisaca          | 22.0           |      |      |

#### Peru

| Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------|----------------|------|------|
| Nazca               | 1.9            |      |      |

### Ecuador

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Meta                      | 25.8           |      |      |
| Guaviús                   | 36.5           |      |      |
| Cayambe                   | 9.6            |      |      |

### Colombia

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Meta                      | 25.8           |      |      |
| Guaviús                   | 36.5           |      |      |
| Caucasia                  | 9.6            |      |      |

### French Guiana

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Guaymar                   | 5.2            |      |      |

### Venezuela

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Lara                      | 6.9            |      |      |
| Lara                      | 6.4            |      |      |
| Sucre                     | 22.1           |      |      |

### Panama

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Panamá Oeste              | 17.6           |      |      |
| Central region of Panama  | 11.1           |      |      |

### Nicaragua

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| North Caribbean Coast     | 9.0            |      |      |

### Costa Rica

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Alajuelita, Heredia, San José | 27.7     |      |      |
| Barva and Heredia         | 6.4            |      |      |
| Guanacaste                | 5.2/1.6        |      |      |

### Grenada

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Saint George              | 4.3            |      |      |

### Mexico

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Campeche                  | 7.6            |      |      |
| Mexico State              | 24.9           |      |      |
| Mexico State              | 21.0           |      |      |
| Mexico State              | 34.0           |      |      |
| Mexico State              | 9.6            |      |      |
| Mexico State              | 8.0            |      |      |
| Mexico State              | 20.2/24.1     |      |      |
| Mexico State              | 0.24/0.0      |      |      |
| Mexico State              | 8.7            |      |      |
| Mexico State              | 17.3           |      |      |
| Mexico State              | 10.2           |      |      |
| Mexico State              | 8.1            |      |      |
| Mexico State              | 4.4            |      |      |
| Mexico State              | 5.0            |      |      |
| Veracruz                  | 4.6            |      |      |

### United States

| State/Province/Department | Prevalence (%) | Dogs | Cats |
|---------------------------|----------------|------|------|
| Texas                     | 14.1           |      |      |
| Texas                     | 2.6            |      |      |
| Texas                     | 6.6            |      |      |
| Texas                     | 6.0            |      |      |
| Texas                     | 3.6            |      |      |
| Texas                     | 7.5            |      |      |
| Texas                     | 13.2           |      |      |
| Texas                     | 16.8           |      |      |
| Texas                     | 18.1           |      |      |
| Texas                     | 28.6           |      |      |

---

**Fig. 5** Seroprevalence of Chagas disease in dogs and cats in different endemic countries of North, Central and South America.
is associated with severe inflammation and necrosis along the A-V conduction tissue. Specific treatment of dogs with severe acute disease often results in regression of histologic and ECG changes [104].

Dogs that survive the acute phase enter the undetermined phase, characterized by the lack of clinical signs and subpatent parasitemia [13]. Some dogs will progress to develop chronic disease, typified by cardiac alterations, including chronic myocarditis with cardiac dilation [13, 105, 106]. During this phase electrocardiogram abnormalities become more evident [13, 107, 108]. Other lesions are associated with fibrosis and cardiomyocyte necrosis, possibly caused by the inflammatory processes that trigger hyalinization and fibrosis [107–110]. Right-side and, eventually, left-side chamber failure may occur, inducing pulse deficits, ascites, pleural effusion, hepatomegaly and jugular venous congestion [13, 111, 112]. In general, naturally infected dogs showed hyperproteinemia, low hemoglobin and hematocrit levels, hypoalbuminemia, hyperglobulinemia, high lactate dehydrogenase (LDH) and aspartate transferase (AST) levels, creatine kinase (CK) and creatine kinase myocardial
band (CK-MB) and troponin I profiles consistent with active myocarditis [113–116].

Chagasic megaesophagus and megacolon can be observed in both the acute and chronic phases [117]. In the acute phase, *T. cruzi* triggers an inflammatory reaction in the esophagus/colon and causes myenteric denervation. Ganglionitis and periganglionitis of the Auerbach’s plexus ranged from mild to moderate and resulted in significant neuronal lesions in dogs experimentally infected with *T. cruzi* strain Berenice-78 [118]. In the chronic phase, persistent myenteric denervation occurs and may lead to impaired digestive function. Glial cell involvement occurs in the acute phase and may lead to a decrease in the glial fibrillary acidic protein immunoreactive area of enteric glial cells in the chronic phase [117].

Prognosis may be unpredictable and the survival rate of chronically infected, untreated dogs is variable. For instance, dogs diagnosed with CD at an older age tend to survive longer than dogs diagnosed at a younger age [13]. A study showed that a combination of amiodarone and itraconazole may increase the survival time of *T. cruzi*-infected dogs [119]. On the other hand, a recent study showed that two dogs with severe, symptomatic Chagas cardiomyopathy treated with itraconazole and amiodarone died suddenly within 6 months of diagnosis [120]. These findings underscore the need for early recognition of CD in dogs and continued research to develop effective antiparasitic treatment protocols.

*Trypanosoma cruzi* infection and CD in cats
Chagas disease in cats is not as well studied as in dogs. Risk factors for the development of CD in cats are still unclear, but it appears that free-roaming cats are more susceptible to *T. cruzi* infection and are an important risk factor for transmission to humans [37]. Indeed, xenodiagnosis data indicated that cats are highly likely to infect peridomestic triatominic vectors [17]. Clinical signs and histologic findings in cats are similar to those described in humans and dogs [121]. Although more common in humans, digestive symptoms such as esophagitis have also been described in *T. cruzi*-infected cats [12]. Neurological signs associated with CD have been described in several species, including dogs [13], but never in cats.

Some cats can mount an effective immune response to *T. cruzi*. However, when immunocompromised or infected with other infectious agents [such as feline infectious peritonitis, feline leukemia virus (FELV), feline immunodeficiency virus (FIV) and feline herpesvirus type 1], they may be more susceptible to *T. cruzi* [37], but this is something that requires further study.

There are few studies on the epidemiology of *T. cruzi* infection in cats (Fig. 5). In a study conducted in three Mexican cities (Mérida, Umán and Tulum) in Yucatán, 7.8% of 95 cats were positive by ELISA and Western blot, using excreted superoxide dismutase as antigen [122]. Interestingly, no infection was observed in other studies conducted in distinct parts of Mexico [32, 38, 39].

A study conducted in Paraná (Brazil) showed 30.8% of 679 cats had anti-*T. cruzi* antibodies detectable by IFAT and 23.6% by ELISA. Only 7.6% of the cats were simultaneously positive to both tests, showing a large discrepancy between these methods [123]. Recent studies in the US revealed 7.3–11.4% of the cats were seropositive in South Texas [12] and Louisiana [124], respectively. Among studies that investigated *T. cruzi* infections in cats, the highest prevalence was reported in Trinidad and Mercedes, two rural villages in the province of Santiago del Estero, Argentina [17]. The authors found an overall seroprevalence of 39–40% in cats at baseline and 1 year later, respectively. Seroprevalence was found to increase with age but was not with sex [17].

Diagnostic methods
In endemic areas, the presence of the above-mentioned clinical signs and clinicopathological abnormalities can lead veterinarians to suspect CD in dogs and cats. In the acute phase, parasitological (e.g., fresh or stained blood preparations, hemoculture and xenodiagnosis) [26] or molecular methods [125] may be useful to confirm the infection (Fig. 7). In addition, molecular methods may be useful for monitoring parasitemia during drug treatment of CD in dogs [126]. However, parasitemia in dogs and cats is generally low and intermittent in the chronic phase [106], which reduces the sensitivity of parasitological and molecular methods. On the other hand, during the chronic phase, anti-*T. cruzi* antibody production reaches detectable titers and can be identified by indirect immunonassays. In dogs, serum immunoglobulin M (IgM) begins to decrease markedly about 3 months after infection, whereas the opposite is true for immunoglobulin G (IgG), which increases up to 15 months and then gradually decreases up to 2 years and then appears to stabilize over the years [127].

Table 1 summarizes serological methods and antigens previously used in studies involving dogs and cats. Some of the tests described were manufactured for the diagnosis of CD in humans, but they have been adapted for dogs and cats. One of the major drawbacks of this adaptation is the lack of phase 1 and phase 2 studies to validate the method in dogs and cats, so the results may not be reproducible. For example, Zecca et al. (2020) used two immunochromatographic tests developed for humans—Chagas Stat-Pak (Chembio Diagnostic Systems, Inc., Medford, NY) and Chagas Detect Plus Rapid Test (InBios International, Inc., Seattle, WA)—to detect anti-*T. cruzi*
antibodies in cats. Although both tests use protein A to detect IgG antibodies, there are no studies validating their use in cats.

Whole-cell homogenates or fractionated lysates of *T. cruzi* epimastigotes have traditionally been used as complex antigen mixtures to detect anti-*T. cruzi* antibodies. Although these combinations have been shown to provide sufficient sensitivity to detect even low antibody levels [128], difficulties in standardization, cross-reactivity and specificity issues have hindered their use in humans [129–132]. This is especially true for IFAT and ELISA results used to diagnosis CD in humans and other species, which may vary depending on the circulating *T. cruzi* strain in the study area and the epimastigote strain used in the tests [65, 133, 134]. Another drawback is the use of different epimastigote strains in IFAT because *T. cruzi* has a high antigenic variation that can lead to false-negative or false-positive results [65], depending on the geographic region.

In the last 2 decades, advances in DNA recombination technology have enabled the use of recombinant proteins in immunoassays (primarily ELISA and chemiluminescence assays), as large quantities of purified antigens can be produced in transformed prokaryotic cells grown in bioreactors [135]. Approximately 25% of the proteins expressed by *T. cruzi* contain tandem repeat amino acid sequences consisting of 5–68 amino acids [136–139]. This improved recognition by antibodies compared to proteins that lack repeated sequences [130, 140, 141] and improved the performance of immunoassays compared to cell extracts or whole epimastigotes [136, 142]. Indeed, sera from infected humans often contain high titers of antibodies against these repeated sequences [143–145]. However, it has been observed that assays
Table 1  Serological tests and antigens used in studies with dogs and cats

| Method | Antigen or manufacturer                                                                 | Performance assessment? | Sample and sample size     | References |
|--------|-----------------------------------------------------------------------------------------|-------------------------|----------------------------|------------|
| EIA    | Whole lysate extracted from epimastigotes of Colombian *T. cruzi* strains Cas-15 and Gal-61 | No                      | Serum D (n = 251)          | [178]      |
| IFAT   | Complete epimastigotes of Colombian *T. cruzi* strains Cas-15 and Gal-61                 |                         |                            |            |
| IHA    | Chagastest HAI test (Wiener Laboratories Rosario, Argentina)                             |                         |                            |            |
| EIA    | TSSApep lineage-specific                                                                | No                      | Serum D (n = 85) C (n = 19) A (n = 7) | [179]      |
| RDT    | Chagas Sero K-SeT RDT                                                                   |                         | D (n = 54)                 | [180]      |
| EIA    | Laboratorio-Lemos SRL, Buenos Aires, Argentina                                           | No                      | Serum D (n = 291)          | [32]       |
| IHA    | Polychaco, Laboratorio-Lemos SRL, Buenos Aires, Argentina                               |                         |                            |            |
| IFAT   | According to [180]—(Tulahuén strain)                                                   | No                      | Serum D (n = 182)          | [181]      |
| EIA    | ELISA of Biozyma kit (Polychaco)                                                        |                         |                            |            |
| IHA    | Hemacruzi (BioMerieux)                                                                  |                         |                            |            |
| IFAT   | According to [180]—(Tulahuén strain)                                                   | No                      | Serum D (n = 330)          | [65]       |
| IHA    | Polychaco S.A.I.C, Buenos Aires, Argentina                                              |                         |                            |            |
| IFAT   | Complete epimastigotes of F90 and Y88 strains                                            | No                      | Serum D (n = 67)           | [85]       |
| EIA    | Chimeric recombinant proteins IBMP                                                      | No                      | Serum D (n = 303)          | [124]      |
| RDT    | InBios Stat-Pak rapid test                                                              |                         |                            |            |
| EIA    | T. cruzi parasite lysate from strain WB1                                                | No                      | Serum D (n = 284)          | [182]      |
| RDT    | Trypanosoma Detect2 MRA Rapid Test. Inbios International Ltd., Washington, USA          | No                      | Serum C (n = 199)          | [185]      |
| EIA    | Whole lysate extracted from epimastigotes of NC-9 strain                                | No                      | Serum D (n = 86) C (n = 38) | [17]       |
| IFAT   | Complete epimastigotes of NC-9 strain                                                   |                         |                            |            |
| IFAT   | Complete epimastigotes of Panamanian Burunga strain                                     | No                      | Serum D (n = 99)           | [92]       |
| EIA    | ELISA Chagastest. Wiener Lab., Argentina modified with whole lysate extracted from epimastigotes of Panamanian Burunga strain |                         |                            |            |
| EIA    | Iron superoxide dismutase—FeSODe                                                      | No                      | Serum D (n = 303)          | [41]       |
| WB     | Iron superoxide dismutase—FeSODe                                                      |                         |                            |            |
| IFAT   | According to [180]                                                                     | Yes                     | Serum D (n = 481)          | [183]      |
| IHA    | Polychaco SAIC, Buenos Aires, Argentina                                                  |                         |                            |            |
| CFT    | According to [184]                                                                     |                         |                            |            |
| DAT    | Polychaco SAIC, Buenos Aires, Argentina                                                  |                         |                            |            |
| IHA    | Polychaco, Buenos Aires, Argentina                                                      |                         |                            |            |
| EIA    | Homogenate of the flagellar fraction of *T. cruzi*                                     | No                      | Serum D (n = 86) C (n = 38) | [17]       |
| IFAT   | According to [180]—(Tulahuén strain)                                                   |                         |                            |            |
| RDT    | Trypanosoma Detect, Inbios, Washington, USA                                             | Yes                     | Serum D (n = 199)          | [185]      |
| IHA    | Polychaco, Buenos Aires, Argentina                                                      |                         |                            |            |
| EIA    | ELISA A: anti-IgG-HRP, Santa Cruz Biotechnology, Santa Cruz, CA                         |                         |                            |            |
| EIA    | ELISA B: using recombinant trans-Sialidase as antigen                                  |                         |                            |            |
| IFAT   | Fluorescein-conjugated anti-gammaglobulin LID, Laboratorio Immunodiagnostico, Buenos Aires, Argentina |                         |                            |            |
| WB     | TESA-blotting, BioMerieux based on strain Y                                            | No                      | Serum D (n = 111)          | [83]       |
| RDT    | Chagas StatPak® Assay, Chembio, USA                                                    | No                      | Serum D (n = 153)          | [86]       |
| EIA    | Total proteins from Querétaro strain of *T. cruzi*                                     | No                      | Serum D (n = 209)          | [42]       |
| WB     | Total proteins from Querétaro strain of *T. cruzi*                                     |                         |                            |            |
| IFAT   | Complete epimastigotes of Colombian *T. cruzi* strains l00/BR/00F (Tcl) and MHOM/BR/1957/Y (Tcl) | No                      | Serum D (n = 62) WM (n = 36) | [64]       |
| EIA    | ELISA, Bio-Manguinhos, Rio de Janeiro, Brazil                                           |                         |                            |            |
using recombinant proteins can also lead to false-negative results [130]. The high genetic variability of the parasite may be responsible for these results, as the tandem repeat amino acid sequences contain a limited repertoire of antigenic determinants that are not expressed or only partially expressed in some T. cruzi strains [146]. To overcome this limitation, several studies have described the combined use of two or more recombinant proteins in a single assay to increase sensitivity without losing specificity [147–151]. In theory, this strategy could compromise assay performance due to imbalanced binding of these epitopes to the solid surface, competition for binding and spatial distribution of epitopes in the solid phase. However, immunoassays containing a mixture of fusion proteins showed good performance [136]. More recently, an array of different antigens printed in each well of 96-well plates has been shown potentially useful for the diagnosis of human chronic CD [152].

In recent years, synthetic chimeric recombinant antigens consisting of conserved repetitive amino acid fragments of different antigenic T. cruzi proteins have been proposed to improve the accuracy of immunoassays for the diagnosis of human CD [130, 136, 153]. In 1999, a study investigated the diagnostic potential of a branched synthetic peptide (2/D/E/Lo1.2) and a linear recombinant peptide (r2/D/E/Lo1.2). The results showed that both antigens increased the reactivity of weakly reactive sera [137]. High diagnostic performance was obtained in a study examining antigens CP1, CP2 or a mixture between them. CP1 contains repetitive fragments of flagellar repetitive antigen (FRA) and shed acute phase antigen (SAPA), whereas CP2 consists of amino acid sequences of three antigens: FRA, SAPA and B13 [136]. The discriminative ability values obtained for CP1 and CP2 were 25% and 52% higher, respectively, than those of their individual antigen mixtures. CP2 was the only antigen that showed higher discriminative capability between T. cruzi-positive and -negative samples compared to the homogenate of the whole parasite [136]. Similar results were obtained with a chimeric antigen designated TcBCDE, a 24-kDa fusion protein composed of repetitive sequences of nine T. cruzi proteins (MAP, JL8, CRA, B13, TcD, TcE and SAPA). This antigen was evaluated and proven to be highly sensitive for the diagnosis of human CD [154]. A chimeric protein called CP3, composed of the antigenic determinants microtubule-associated protein (MAP), TcD and trypomastigote small surface antigen (TSSA)-II/V/VI, was 100% sensitive and 90.5% specific [155]. These results not only demonstrate that chimeric recombinant proteins are highly accurate in the diagnosis of chronic CD, but also that they are able to detect anti-T. cruzi antibodies regardless of parasite strain or gene expression intensity. In addition, these findings support the utility of performing immunochromatographic assays with hybrid, chimeric single-molecule antigens rather than peptide mixtures or recombinant proteins.

Recently, four chimeric recombinant T. cruzi antigens have been proposed for the diagnosis of chronic CD in humans: IBMP-8.1, IBMP-8.2, IBMP-8.3 and IBMP-8.4 (IBMP is the Portuguese acronym for Biology Molecular

### Table 1 (continued)

| Method          | Antigen or manufacturer                                                                 | Performance assessment | Sample and sample size | References |
|-----------------|----------------------------------------------------------------------------------------|------------------------|------------------------|------------|
| EIA             | Plates of Chagas III ELISA kit (Grupo Bios®) and monoclonal secondary antibody goat anti-dog IgG-HRP: sc-2433 (Santa Cruz Biotechnology, INC) | No                     | Serum D (n = 356)      | [48]       |
| IFAT            | N.I.H.—Colombia                                                                        |                        |                        |            |
| RIPA            | Tulahuen strain epimastigote lystate                                                   |                        |                        |            |
| RDT             | Chagas Sero K-SeT (TSSA peptide epitope specific to TcII/V/VI)                         | Yes                    | D (n = 57)             | [172]      |
| RIPA            | Tulahuen strain epimastigote lystate                                                   |                        |                        |            |
| RDT             | Chagas Stat-Pak (Chembio, Medford, NY, USA)                                            | No                     | Serum D (n = 301)      | [57]       |
| EIA             | Whole parasite lystate from a local strain WB1                                          |                        |                        |            |
| WB              | Whole parasite lystate from a local strain WB1                                          |                        |                        |            |
| RDT             | Chagas Stat-Pak (Chembio, Medford, NY, USA)                                            | No                     | Serum D (n = 540)      | [56]       |
| IFAT            | Texas Veterinary Medical Diagnostic Laboratory (TVMDL, College Station, TX)            |                        |                        |            |
| EIA             | Recombinant proteins PGR31-His, PGR30-His and PGR24-His                                 | No                     | Serum D (n = 333)      | [93]       |
| MABA            | Recombinant proteins PGR31-His, PGR30-His and PGR24-His                                 | No                     | Serum D (n = 40)       | [69]       |
| EIA             | Modified Gold ELISA Chagas commercial test Chimeric recombinant proteins IBMP          | No                     | Serum Dogs (n = 40)    |            |

A (armadillos), C (cats), CFT (complement fixation test), D (dogs), DAT (direct agglutination test), IBT (immunoblot test), IFAT (immunofluorescence antibody test), MABA (microplate alamar blue assay), RDT (rapid diagnostic test/immunochromatography), WB (Western blot), WM (wild mammals), TSSA (mucin trypomastigote small surface antigen)
Instituto of Paraná, where the antigens were expressed and purified). The diagnostic potential of these proteins for the detection of CD in humans has been extensively studied, using different diagnostic methods and platforms such as indirect ELISA [129, 156–161], liquid microarray [162], lateral flow assay [163], double-antigen sandwich ELISA [164], Western blot (unpublished data) and immunosensor [165]. IBMP antigens are composed of different epitopes of several T. cruzi proteins, as described in Fig. 8 [156, 159, 166]. In general, this diversity of antigenic determinants is responsible for their high reactivity to anti-T. cruzi antibodies.

The ability of IBMP antigens to discriminate T. cruzi-positive from -negative human samples was evaluated, and the area (AUC) under the receiver-operator curve was determined for each molecule. The determination of AUC values is used as the global accuracy of immunoassays [129] and can be classified as low (51–61%), moderate (62–81%), elevated (82–99%) or outstanding (100%) [167]. Accordingly, AUC values ranged from 98.4% to 100% and from 97.8% to 99.7% when positive and negative samples were assayed with IBMP antigens using indirect ELISA and liquid microarray, respectively, as diagnostic platforms [129]. These results indicate that all four IBMP antigens have high discriminatory capability. Considering the high overall accuracy values, the IBMP antigens were used to participate in a phase II study with T. cruzi human positive and -negative samples from different geographic endemic regions of Brazil and other endemic countries using indirect ELISA [156–158] and liquid microarray [162]. Sensitivity, specificity and diagnostic odds ratio values were obtained that were higher than those obtained with commercial tests [156–158, 162, 168]. Cross-reactivity with Leishmania spp. was extremely low in patients with American cutaneous and visceral leishmaniasis [160]. In light of the negligible cross-reactivity, the authors recommend the use of IBMP antigens in regions where T. cruzi and Leishmania spp. are co-endemic [160]. In 2020, Silva et al. [163] proposed a lateral flow assay using IBMP-8.1 and IBMP-8.4 chimeric antigens for the diagnosis of CD in humans. The study showed that the assay can correctly diagnose both T. cruzi-positive and -negative individuals regardless of geographic origin or clinical presentation. AUC values were 100%, demonstrating an outstanding diagnostic accuracy. The study showed that the lateral flow assay based on these antigens is a promising method for screening CD [163]. In 2020, this device was licensed by the Brazilian Health Regulatory Agency to form the portfolio of diagnostic products of the Brazilian Ministry of Health for use in the Unified Health System: the TR-Chagas Bio-Manguinhos (Oswaldo Cruz Foundation, Rio de Janeiro, Brazil).
Janeiro, RJ, Brazil) [169]. Recently, all four IBMP antigens have shown promising results in a phase 3 study with more than 5000 samples from a Brazilian blood bank, especially the IBMP-8.3 and IBMP-8.4 antigens [161].

With the exception of IBMP antigens, all chimeric recombinant proteins discussed here (CP1, CP2, CP3, 2/D/E/Lo1.2, r2/D/E/Lo1.2, TcBCDE) have been evaluated only for human diagnostics. As mentioned previously, there are no commercial tests for the diagnosis of CD in dogs and cats. In 2019, a phase I study investigated the diagnostic performance of IBMP antigens in dogs [170]. AUC values ranged from 91–100%, demonstrating good diagnostic performance of these molecules also for the diagnosis of CD in dogs. Cordeiro et al. [165] reached the same conclusion by showing that IBMP-8.1 reached a maximum AUC value for both human and canine samples using an impedimetric immunosensor for rapid detection of anti-\textit{T. cruzi} antibodies. Recently, two recombinant \textit{T. cruzi} proteins (IBMP-8.1 and IBMP-8.4) were tested as diagnostic platforms using a rapid immunochromatographic assay (TR Chagas, Bio-Manguinhos, Rio de Janeiro, Brazil) [171]. Recombinant antigens were formatted in a rapid immunochromatographic assay using either \textit{Staphylococcus aureus} protein A or \textit{Streptococcus pyogenes} protein G as gold-labeled reagents to visualize the precipitin band formed between immunoglobulin (Ig) G-specific antibodies and the recombinant antigen immobilized on the nitrocellulose strip used in the assay. Protein A and protein G were based on the fact that these microbial molecules bind with different affinity and specificity to immunoglobulins of different species, including dogs. The authors found that the intensity pattern of the bands was directly proportional to the serological titer in IFAT. The sensitivity was 94% and the specificity was 91%. The agreement obtained was considered substantial by kappa analysis (84%). Of the \textit{T. cruzi}-positive hemoculture samples, 88.9% were positive with TR-Chagas Bio-Manguinhos. The assay was efficient in detecting infections with five of the six \textit{T. cruzi} discrete typing units (DTU; Tcl, n = 8; TcII, n = 1; Tcl/TcII, n = 2; TcIII, n = 2; TclV, n = 1; TclII/TcV, n = 6). Cross-reactions were not observed in infections with Leishmania infantum, Trypanosoma rangeli, Trypanosoma caninum and Dirofilaria immitis, but were observed in sera from dogs infected with \textit{Crithidia mellificae}, Anaplasm spp. and \textit{Ehrlichia} spp. However, the authors used a convenient serum panel for cross-reactivity analysis, many of which had only a single sample per disease. Therefore, further studies should be conducted to confirm or refute these results. This test provides rapid preventive measures in areas at high risk for Chagas disease occurrence in a safe, reliable, cost-effective and immediate manner without the need for more complex laboratory testing. In 2020, the diagnostic performance of a rapid test based on trypomastigote small surface antigen (TSSA) was evaluated (namely Chagas Sero K-SeT). However, low sensitivity for the diagnosis of Chagas disease in dogs was observed (28%; 16/57), indicating the need for further studies to improve test performance [172].

Conclusion

Although the detection of anti-\textit{T. cruzi} antibodies is possible in any mammalian species, serological tests may give discrepant results in different situations. This is mainly due to the high genetic and phenotypic intraspecific diversity of \textit{T. cruzi} [173, 174], the selection of antigens used to sensitize the solid phase of immunoassays [133], the variable prevalence of the disease [175, 176] and the variable immune responses in \textit{T. cruzi}-infected individuals [177]. The development of commercial diagnostic tools to detect past exposure to \textit{T. cruzi} in dogs and cats would be useful from both veterinary and public health perspectives. Such a test should be able to detect antibodies regardless of the geographical region and the circulating DTU, with high sensitivity, specificity and accuracy, as well as with low risk of cross-reactivity (especially with \textit{Leishmania} spp.). Furthermore, the test should be rapid (rapid diagnostic test), inexpensive and easy-to-use under field conditions (point-of-care test). Data show that the chimeric recombinant antigens combine all the necessary characteristics for a test with good applicability for epidemiological surveillance in veterinary clinical practice and in animal blood centers.

Abbreviations

A: Armadillos; AST: Aspartate transferase; AUC: Area under the receiver-operator curve; C: Cats; CD: Chagas disease; CFT: Complement fixation test; D: Dogs; DAT: Direct agglutination test; DeCS: Health sciences descriptors; CK: Creatine kinase; CK-MB: Creatine kinase myocardial band; DNA: Deoxyribonucleic acid; DTU: Discrete typing units; ECG: Electrocardiogram; ELISA: Enzyme-linked immunosorbent assay; FELV: Feline leukemia virus; FIV: Feline immunodeficiency virus; FRA: Flagellar repetitive antigen; IBMP: Portuguese acronym for Biology Molecular Institut of Panânia; IBT: Immunoblot test; IFAT: Immunofluorescence antibody test; IgG: Immunoglobulin G; IgM: Immunoglobulin M; MABA: Microplate Alamar Blue Assay; MAP: Microtubule-associated protein; PRISMA: Preferred reporting items for systematic reviews and meta-analyses; RDT: Rapid diagnostic tests/immunochromatography; Scielo: Scientific electronic library online; SAPA: Shed acute phase antigen; TSSA: Mucin trypomastigote small surface antigen; WB: Western blot; WM: Wild mammals.

Supplementary Information

The online version contains supplementary material available at \url{https://doi.org/10.1186/s13071-022-05476-4}.

Additional file 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

[Supplementary Material]
Acknowledgements

Figures were created with biorender.com.

Author contributions

All authors participated in the conception and design of the study. The systematic review was conducted by NEMF, FLH and FLNS. NEMF, FLH, EFS, AAOS, NDF, LML, DDS and MCA were responsible for writing the manuscript. Images were provided by DDS, MCA and FLNS. The figures were prepared by FLNS. All authors contributed to changes made to subsequent versions from the first version. FDT was responsible for reviewing the final version of the manuscript, and all authors read and approved the final manuscript.

Funding

This research was supported by the Coordination of Superior Level Staff Improvement-Brazil (CAPES; Finance Code 001), the Research Support Foundation of the State of Bahia (FAPESB), and Inova Fiocruz/VPPCB (grant number VPPCB-006-FIO-18-2-20). FLNS is CNPq research fellow (grant number 309263/2020-4). Funders had no role on the study design, data collection and analysis of the State of Bahia (FAPESB); and Inova Fiocruz/VPPCB (grant number VPPCB-006-FIO-18-2-20). FLNS is CNPq research fellow (grant number 309263/2020-4). Funders had no role on the study design, data collection and analysis, decision to publish or preparation of the manuscript.

Availability of data and materials

All the data generated or analyzed during this study are included in the published article.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Filipe Dantas-Torres is Editor-in-Chief of Parasites & Vectors, but the peer review process and final decision was handled independently by the Professor Anna Bajer, Subject Editor of the section Protozoa and protozoan diseases.

Author details

1 Advanced Health Public Laboratory, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Waldemar Falcão Street, 121, Candeal, Bahia, Salvador 40296-710, Brazil. 2 Brazil’s Family Health Strategy, Municipal Health Department, Tremedal City Hall, Bahia, Tremedal, Brazil. 3 Pathology and Molecular Biology Laboratory, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Bahia, Brazil. 4 Laboratory of Immunoparasitology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil. 5 Integrated Translational Program in Chagas Disease From Fiocruz (Fio-Chagas), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. 6 Manne-Goehler J, Reich MR, Wirtz VJ. Access to care for Chagas disease in the United States: a health systems analysis. Am J Trop Med Hyg. 2015;93:108–13. 7 Conners EE, Vinetz JM, Weeks JR, Brouwer KC. A global systematic review of Chagas disease prevalence among migrants. Acta Trop. 2016;156:68–78. 8 Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1:92–100. 9 Carvalho EB, Ramos IP, Nascimento AFS, Brasil GV, Mello DB, Oti M, et al. Echocardiographic measurements in a preclinical model of chronic chagasic cardiomyopathy in dogs: validation and reproducibility. Front Cell Infect Microbiol. 2019;9:1–8. 10 Guedes PMM, Veloso VM, Callari MV, Carneiro CM, Souza SM, de Lana M, et al. Trypanosoma cruzi high infectivity in vitro is related to cardiac lesions during long-term infection in Beagle dogs. Mem Inst Oswaldo Cruz. 2007;102:141–7. 11 Tafuri WL, de Lana M, Chiari E, Callari MV, Bambirra EA, Rios-Leite VH, et al. Dogs as experimental models for the study of the natural course of Chagas disease. Rev Soc Bras Med Trop. 1988;21:77. 12 Zecca IB, Hodo CL, Slack S, Auckland L, Rodgers S, Killets KC, et al. Prevalence of Trypanosoma cruzi infection and associated histologic findings in domestic cats (Felis catus). Vet Parasitol. 2020;278:109014. 13 Barr SC. Canine Chagas’ disease (American trypanosomiasis) in North America. Vet Clin North Am Small Anim Pract. 2009;39:1055–64. 14 Maggi RG, Krämer F. A review on the occurrence of companion vector-borne diseases in pet animals in Latin America. Parasites Vectors. 2019;12:1–37. 15 Lima AF, Jeraldo VD, Silveira MS, Madi RR, Santana TB, Melo CM. Triatomines in dwellings and outbuildings in an endemic area of Chagas disease in northeastern Brazil. Rev Soc Bras Med Trop. 2012;45:701–6. 16 Gürtler RE, Ceballos LA, Ordóñez-Krasnowski P, Lanati LA, Sariolo R, Kotron U. Strong host-feeding preferences of the vector Triatoma infestans modified by vector density: implications for the epidemiology of Chagas disease. PLoS Negl Trop Dis. 2009;3:e447. 17 Gürter RE, Cecere MC, Lauricella MA, Cardinal MV, Kotron U, Cohen JE. Domestic dogs and cats as sources of Trypanosoma cruzi infection in rural northwestern Argentina. Parasitology. 2007;134:69–82. 18 Wisnivesky-Colli C, Gürter RE, Solarz ND, Lauricella MA, Segura EL. Epidemiological role of humans, dogs and cats in the transmission of Trypanosoma cruzi in a central area of Argentina. Rev Inst Med Trop Sao Paulo. 1985;27:346–52. 19 Travi BL. Considering dogs as complementary targets of Chagas disease control. Vector borne zoonotic Dis. 2019;19:90–4. 20 Gürter RE, Cardinal MV. Reservoir host competence and the role of domestic and communal hosts in the transmission of Trypanosoma cruzi. Acta Trop. 2015;151:32–50. 21 Blandon R, Leandro IM. Johnson CM [Clinical, electrocardiographic and angiographic evaluation of natural reservoirs of Chagas’ disease in the Republic of Panama]. Rev Med Panama. 1995;20:108–15. 22 Enriquez GF, Cardinal MV, Orozco MM, Schijman AG, Gürter RE. Detection of Trypanosoma cruzi infection in naturally infected dogs and cats using serological, parasitological and molecular methods. Acta Trop. 2013;126:211–7. 23 Castillo-Neyra R, Chou Chiu, Quispé-Machaca V, Ancca-Juarez J, Malaga-Chavez FS, Bastos, Mazuelos M, et al. The potential of canine sentinel for reemergent Trypanosoma cruzi transmission. Prev Vet Med. 2015;120:349–56. 24 Page MJ, McKenzie J, Bossuyt PM, Bouton I, Hoffmann TC, Mollov CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18:1–15. 25 Roellig DM, Ellis AE, Yabsley MJ. Oral transmission of Trypanosoma cruzi with opposing evidence for the theory of carnivory. J Parasitol. 2009;95:360–4. 26 Jansen AM, Luiz A, Roque R, Maria A, Jansen AM. Importância dos animais domésticos sentinelas na identificação de áreas de risco de emergência de doença de Chagas. Rev Soc Bras Med Trop. 2008;41:191–3. 27 Enriquez GFF, Bua J, Orozco MMM, Wirth S, Schijman AGG, Gürter RE, et al. High levels of Trypanosoma cruzi DNA determined by qPCR and infectiousness to Triatoma infestans support dogs and cats are
major sources of parasites for domestic transmission. Infect Genet Evol. 2014;25:36–43.

28. Coura JR, Petana WB. Additional data on the epidemiology of Chagas disease in the municipality of Caxias, Rio de Janeiro state Brazil. Rev Soc Bras Med Trop. 1975;8:93–9.

29. Gurtler RE, Castanera MB, Canale D, Laucelria MA, Chuit R, et al. Probability of infection with Trypanosoma cruzi of the vector Triatoma infestans fed on infected humans and dogs in northwest Argentina. Am J Trop Med Hyg. 1996;55:24–31.

30. Coffield DJ, Spagnuolo AM, Shillor M, Mema E, Peltzus N, et al. A model for Chagas disease with oral and congenital transmission. PLoS ONE. 2013;8:e67267.

31. Jiménez-Coello M, Guzmán-Márín E, Ortega-Pacheco A, Acosta-Viana KY. Serological survey of American trypanosomiasis in dogs and their owners from an urban area of Mérida Yucatán Mexico. Transbound Emerg Dis. 2010;57:33–6.

32. Quijano-Hernández IA, Castro-Barcena A, Barbabosa-Pliego A, Ochoa-García L, Del Ángel-Caraza J, Vázquez-Chagoyán JC. Seroprevalence survey of American trypanosomiasis in Central Valley of Toluca. Sci World J. 2012;1:1–3.

33. Balan LU, Yerbes IM, Pina MAN, Balmes J, Pascual A, Hernández O, et al. American trypanosomiasis and toxoplasmosis infection in domestic owned cats from the tropical southeast of Mexico. Zoonoses Public Health. 2012;59:102–9.

34. Barbabosa-Pliego A, Gil PC, Hernández DO, Aparicio-Burgos JE, de Oca-Villagrán M, Jiménez-Delgadillo B, et al. Seropositivity for Trypanosoma cruzi infection in dogs and domestic free roaming dogs and cats from a marginated rural area of Yucatan Mexico. Vet Med Sci. 2017;3:40–7.

35. Mejía A, Portugal-García V, Chávez-López V, García-Vázquez Z, Ramos C. Evidencia serológica de infección por Trypanosoma cruzi en perros atendidos en clínicas veterinarias del área conurbada de Cuernavaca. Morelos Salud Publica Med. 2017;59:205–6.

36. Estrada-Franco JG, Bhatia V, Diaz-Albiter H, Ochoa-García L, Barbabosa A, Vazquez-Chagoyan JC, et al. Human Trypanosoma cruzi infection and seropositivity in dogs. Mexico Emerg Infect Dis. 2006;12:624–30.

37. Jiménez-Coello M, Acosta-Viana KY, Guzman-Marín E, Gomez-Rios A, García-Vazquez Z, Rosario-Cruz R, Miranda-Miranda E, Dominguez-Dias J. Seroprevalence of Trypanosoma cruzi infection in domestic owned cats from south of Yucatan Mexico. Vet Med Sci. 2017;3:40–7.

38. Tenney TD, Curtis-Robles R, Meyers AC, Auckland LD, Zecca IB, Skiles R, Hamer SA. Shelter dogs as sentinels for Trypanosoma cruzi transmission across Texas. Emerg Infect Dis. 2014;20:1323–6.

39. Montenegro VW, Jimenez M, Dias JCP, Zeledon R. Chagas disease in dogs from endemic areas of Costa Rica. Mem Inst Oswaldo Cruz. 2020;115:1–5.

40. Reyes L, Silesky E, Cerda C, Chinchilla M, Guerrero O. Presencia de anticuerpos contra Trypanosoma cruzi en perros de Costa Rica. Parasitol Latinoam. 2002;57:66–8.

41. Bonilla MC, Castro-Vázquez RM, Herrero-Acosta MV, Urbina-Villalobos A, Dolz G. Canine trypanosomiasis in an endemic Costa Rican community. Demonstration of the active infection cycle. Vet Parasitol Reg Stud reports. 2019;17:100307.

42. Allen KE, Lineberry MW. Trypanosoma cruzi and other vector-borne infections in shelter dogs in two counties of Oklahoma United States. Vector-Borne Zoonotic Dis. 2022;22:273–80.

43. Constantino C, Pellizzaro M, de Paula EFE, Vieira TSWJ, Brandão APD, Ferreira E, et al. Seropositivity for Leishmania spp. Toxoplasma gondii, Trypanosoma cruzi and Neospora caninum in neighborhood dogs in Curitiba-Paraná Brazil. Rev Bras Parasitol Veterinária. 2016;25:504–10.
64. de Oliveira Porfirio GE, Santos FM, de Macedo GC, Barreto WT, Campos JB, Meyers AC, et al. Maintenance of Trypanosoma cruzi, T evansi and Leishmania spp by domestic dogs and wild mammals in a rural settlement in Brazil-Bolivian border. Int J Parasitol Parasites Wildl. 2018;7:398–404.

65. Costa TF, Rocha AVDO, Miranda LM, Lima LFS, Santos FLN, Silva AAO, et al. Seroprevalence and detection of Trypanosoma cruzi in dogs living in a non-endemic area for Chagas disease in the legal Amazon region. Brazil Vet Parasitol Reg Stud Reports. 2021;26:100648.

66. Dario MA, Rodrigues MS, Barros JH, Xavier SC, D’Andrea PS, Roque AL, et al. Ecological scenario and Trypanosoma cruzi DTU characterization of a fatal acute Chagas disease case transmitted orally (Espírito Santo state, Brazil). Parasit Vectors. 2016;9:477.

67. Bezerra CM, Cavalcanti LP, Souza RD, Barbosa SE, Xavier SC, Jansen AM, et al. Domestic, peri-domestic and wild hosts in the transmission of Trypanosoma cruzi in the Caatinga area colonised by Triatoma brasiliensis. Mem Inst Oswaldo Cruz. 2014;109:887–98.

68. Lima MM, Sarquis Q, de Oliveira TG, Gomes TF, Coutinho C, Daflon-Teixeira NF, et al. Investigation of Chagas disease in four perirural areas in northeastern Brazil: Epidemiologic survey in man, vectors, non-human hosts and reservoirs. Trans R Soc Trop Med Hyg. 2012;106:143–9.

69. Santos F, Magalhães-Junior JT, de Carneiro IO, Santos FLN, Silva ÂAO, Bezerra CM, Cavalcanti LP, Souza RD, Barbosa SE, Xavier SC, Jansen AM, et al. Seropositive contact of dogs and wild and Trypanosoma cruzi transmission areas from Brazilian southwestern Amazon: New mammalian host for Trypanosoma cruzi. Acta Trop. 2020;210:105504.

70. Leça Júnior NF, dos Almeida VA, Carvalho FS, Albuquerque GR, Silva FL. First report of Trypanosoma cruzi infection in naturally infected dogs from southern Bahia Brazil. Rev Bras Parasitol Veterinária. 2013;22:182–5.

71. de Souza GB, Guedes PEB, Oliveira TNDA, Carvalho FS, Albuquerque GR, Silva FL. Natural infection by Trypanosoma cruzi in dogs located in Ituberá, Southern Bahia Brazil. Semin Ciências Agrárias. 2018;39:881.

72. Fernandesda ARF, Pimenta CLRM, Vidal IF, Oliveira GC, Santon RS, Araújo RB, et al. Risk factors associated with seropositivity for Leishmania spp and Trypanosoma cruzi in dogs in the state of Paraiba Brazil. Rev Bras Parasitol Veterinária. 2016;25:90–8.

73. Freitas YBN, de Souzada CSF, Magalhães JMV, de Souza MLR, D’Escoffier LN, Valledo TZ, et al. Natural infection by Trypanosoma cruzi in triatomines and seropositivity for Chagas disease of dogs in rural areas of the municipality of São João do Piauí, Piauí state, Brazil. Rev Bras Med Vet. 2018;51:190–7.

74. de Araújo-Neto VT, Honorato NRM, de Santanaro R, Barbosa-Silva AN, Guedesda PMM, Chiar E, et al. Trypanosoma cruzi circulating among dogs and triatomines in the endemic countryside of the State of Rio Grande do Norte Brazil. Acta Trop. 2019;200:105067.

75. Da Paz GS, Da Silva CB, Anton MM, De Souza RK, Da Silva DB, De Moraes CCG, et al. Infection by Toxoplasma gondii, Neospora caninum, Leishmania major and Trypanosoma cruzi in dogs from the state of Pará. Cienc. Anim Bras. 2019;20:1–10.

76. Tome RO, Gaio FC, Generoso D, Menozzi BD, Langoni H. Active surveillance of canine visceral leishmaniasis and American trypanosomiasis in rural dogs from non endemic area. Rev Bras Parasitol Veterinária. 2011;20:4–6.

77. Perez TD, Figueiredo FB, Junior AAMV, Silva VL, de Madeira M, Brazil RP, et al. Prevalence of American trypanosomiasis and leishmaniasis in domestic dogs in a rural area of the municipality of São João do Piauí, Piauí state, Brazil. Rev Inst Med Trop Sao Paulo. 2016;58:79.

78. Xavierdas SCC, Roque ALR, Bilac D, de Araújo VAL, Neto CLRM, Vidal IF, et al. Distantiae transmission of Trypanosoma cruzi in the Gran Chaco: mixed infections and differential host distribution of TcV and TcVI. Infect Genet Evol. 2015;29:53–9.

79. Benitez M, Concepcion JL, Carzola V, Rodriguez J. Seroprevalence of the infection by Trypanosoma cruzi and factors associated in a small mammal. Bol Chil Infecto. 1996;51:76–9.

80. Rios A, Alcaíno H, APT W. Enfermedad de Chagas in canines, bovines and equines in rural areas of the Province del Límarí. Chile Parasitol al día. 1986;10:40–5.

81. Burchard L, Cáceres J, Saguá H, Inés Bahamonde M, Neira L, Araújo J, et al. Current human and canine seroprevalence of Chagas disease in San Pedro de Atacama County, II Region of Antofagasta, Chile, 1995. Bol Chil Parasitol. 1996;51:76–9.

82. Tomas RN, Ferrari J, Espinosa JC, et al. Prevalence of American trypanosomiasis in dogs from Chagas disease endemic regions in Panama Central America. Vet Parasitol. 2011;178:360–3.

83. Bonfante-Cabaracas R, Rodríguez-Bonfante C, Vela BO, García D, Saldivia AV, Aldana E, et al. Seroprevalence of the infection by Trypanosoma cruzi and factors associated in a small mammal. Bol Chil Infecto. 2015;70:936–44.

84. Norma U, Edgar M, Huapaya J. Seroprevalence in animals, equines and Trypanosoma cruzi infection in naturally infected dogs. Rev Horiz. 1985;6:40–5.

85. Rosypal AC, Tripp S, Kinlaw C, Sharma RN, Stone D, Dubey JP. Seroprevalence of canine leishmaniasis and American trypanosomiasis in dogs from Grenada. West Indies J Parasitol. 2010;06:228–9.

86. Grantham A, Bouma M, Bleau D, Esquivel N, Menozzi BD, Lou M, et al. Molecular and serological investigation of Trypanosoma cruzi infection in dogs in the Bolivian Chaco. Parasit Vectors. 2018;11:362.
frequent in dogs from the pacific coast of Ecuador. Microb Pathog. 2021;155:104884.

102. Petersen RM, Gürtler RE, Cecere MC, Rubel DN, Lauricella MA, Hansen D, et al. Association between nutritional indicators and infectivity of dogs sero-reactive for Trypanosoma cruzi in a rural area of westernmost Argentina. Parasitol Res. 2001;87:208–14.

103. Busselman RE, Meyers AC, Zecca IB, Auckland LD, Castro AH, Dowd RE, et al. High incidence of Trypanosoma cruzi infections in dogs directly detected through longitudinal tracking at 10 multi-dog kennels, Texas, USA. PLoS Negl Trop Dis. 2021;15:e0009935.

104. Andrade ZA, Andrade SG. Pathology of experimental Chagas disease in dogs. Mem Inst Oswaldo Cruz. 1980;75:77–95.

105. Pellegrino J. O eletrocardiograma na fase crônica da doença de Chagas experimental no cão. Mem Inst Oswaldo Cruz. 1946;44:615–47.

106. Eloy L, Luchesi S. Canine trypanosomiasis: etiology of infection and implications for public health. J Venom Anim Toxins incl Trop Dis. 2009;15:589–611.

107. Barbabosa-Piélego A, Diaz-Albiter HM, Ochoa-García L, Aparicio-Burgos MP, de Lana M, Chiari E, Tafuri WL. Experimental Chagas' disease in dogs. Mem Inst Oswaldo Cruz. 1992;87:59–71.

108. Matthews DJ, Saunders AB, Gordon SG, Hamer SA. Cardiac myocarditis in dogs treated with low doses of cyclophosphamide. Am J Pathol. 1987;127:467–73.

109. de Lana M, Chiani E, Tafuri WL. Experimental Chagas' disease in dogs. Mem Inst Oswaldo Cruz. 1992;87:59–71.

110. Meyers AC, Ellis MM, Purnell JC, Auckland LD, Meinders M, Saunders AB, et al. Selected cardiac abnormalities in Trypanosoma cruzi serologically positive, discordant, and negative working dogs along the Texas-Mexico border. BMC Vet Res. 2020;16:101.

111. Matthews DJ, Saunders AB, Meyers AC, Gordon SG, Hamer SA. Cardiac diagnostic test results and outcomes in 44 dogs naturally infected with Trypanosoma cruzi. J Vet Intern Med. 2021;35:1800–9.

112. Stoner CH, Saunders AB. Cardiac manifestations of Trypanosoma cruzi infection in a domestic dog. Case Reports. 2020;24:410–4.

113. de Souza AJ, Paulino-Junior D, Souza MG, Camacho AA. Aspectos clínico-laboratoriais da infecção natural por Trypanosoma cruzi em cães de Mato Grosso do Sul. Ciência Rural. 2008;38:1351–6.

114. Santana VL, Souza AP, Lima DASD, Araújo AL, Justiniano SV, Dantas RP, et al. Caracterização clínica e laboratorial de câes naturalmente infectados com Trypanosoma cruzi no semiárido nordestino. Pesqui Vet Bras. 2012;32:536–41.

115. Nogueira-Paiva NC, Fonseca KS, Vieira PMA, Diniz LF, Caldas IS, Moura YM. Chronic Chagas disease diagnosis: a comparative performance of commercial enzyme immunoassay tests. J Vet Diagn Invest. 2019. https://doi.org/10.1177/1040638719868508.

116. Santos FLN, Celedon PAF, Zanini N, Bilardo CL, de Souza WV, et al. Performance assessment of four chimeric Trypanosoma cruzi antigens based on antigen-antibody detection for diagnosis of chronic Chagas disease. PLoS ONE. 2016;11:e0161100.

117. Da Silveira JF, Umezawa ES, Luquetti AO. Chagas disease: recombiant Trypanosoma cruzi antigens for serological diagnosis. Trends Parasitol. 2001;17:286–91.

118. Saez-Alquezar A, Sabino EC, Salles N, Chamone DF, Hulstaert F, Pottel H, et al. Serological confirmation of Chagas' disease by a recombinant and peptide antigen line immunocapture. J Clin Microbiol. 2000;38:851–4.

119. Gomes YM, Lemeva VB, Luquetti AO. Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies? Mem Inst Oswaldo Cruz. 2009;104:115–21.

120. Santos FLN, Souza WV, Barros MS, Nakazawa M, Krieger MA, Gomes YM. Chronic Chagas disease diagnosis: a comparative performance of commercial enzyme immunoassay tests. J Am Trop Med Hyg. 2016;94:1034–9.

121. Luciano RM, Luchesi SB, Troncarelli MZ, Luciano DM, Langoni H. Cross reaction evaluation of Leishmania spp and Trypanosoma cruzi antigens in dogs' serologic response by indirect immunofluorescence test (IIF). Brazilian J Vet Res Anim Sci. 2009;46:181.

122. Tripathi NK, Shrivastava A. Recent developments in bioprocessing of recombinant proteins: expression hosts and process development. Front Bioeng Biotechnol. 2019;7:420.

123. Camussone C, Gonzalez VV, Belluzzo MSM, Pujato N, Ribone MEME, Lagier CM, et al. Comparison of recombinant Trypanosoma cruzi peptide mixtures versus multipeptide chimeric proteins as sensitizing antigens for immunodiagnosis. Clin Vaccine Immunol. 2009;16:899–905.

124. Houghton RL, Benson DR, Reynolds LD, McNeill PD, Sleath PR, Lodes MJ, et al. A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation—confirmed and consensus-positive sera. J Infect Dis. 1999;179:1226–34.

125. Lafaille JJ, Linss J, Krieger MA, Souto-Padrón T, de Souza W, Goldenberg S. Structure and expression of two Trypanosoma cruzi genes encoding antigenic proteins bearing repetitive epitopes. Mol Biochem Parasitol. 1989;35:127–36.

126. Araujo FG. Analysis of Trypanosoma cruzi antigens bound by specific antibodies and by antibodies to related trypanosomatids. Infect Immun. 1986;53:179–85.

127. Goto Y, Carter D, Reed SG. Immunological dominance of Trypanosoma cruzi tandem repeat proteins. Infect Immun. 2008;76:3967–74.
141. Buscaglia Ca, Campetella O, Leguizamón MS, Frasch Ca. The repetitive
domain of Trypanosoma cruzi trans-sialidase enhances the immune
response against the catalytic domain. J Infect Dis. 1998;177:431–6.
142. Valiente‑Gabioud Aa, Veaute C, Perrig M, Galan‑Romano FS, Sterco
SJ, Marcipar IS. Effect of repetitiveness on the immunogenicity
and antigenicity of Trypanosoma cruzi FRA protein. Exp Parasitol.
2011;127:672–9.
143. Frasch AC, Cazzulo JJ, Aslund L, Pettersson U. Comparison of genes
encoding Trypanosoma cruzi antigens. Parasitol Today. 1997;1:148–51.
144. Hoff DF, Kim KS, Otsu K, Moser DR, Yost WJ, Blumín JH, et al. Trypa-
osoma cruzi expresses diverse repetitive protein antigens. Infect
Immun. 1989;57:59–67.
145. Umezawa ES, Luquetti AO, Levitus G, Ponce C, Ponce E, Henriquez D,
et al. Serodiagnosis of chronic and acute Chagas disease with Trypa-
osoma cruzi recombinant proteins: results of a collaborative study in
six Latin American countries. J Clin Microbiol. 2004;42:449–52.
146. De Pablos LM, Osuna A. Multigene families in Trypanosoma cruzi
and their role in infectivity. Infect Immun. 2012;80:2268–9.
147. Almeida E, Krieger MA, Carvalho MR, Oelemann W, Goldenberg S.
Use of recombinant antigens for the diagnosis of Chagas disease and
blood bank screening. Mem Inst Oswaldo Cruz. 1990;85:13–7.
148. Krieger MA, Almeida E, Oelemann W, Lafaille VC, Pereira JB, Krieger H,
et al. Use of recombinant antigens for the accurate immunodiagnosis
of Chagas disease. Am J Trop Med Hyg. 1994;42:1265–34.
149. Carvalho MR, Krieger MA, Almeida E, Oelemann W, Shikanai‑Yasuda
MA, Ferreira AW, et al. Chagas' disease diagnosis: evaluation of several
tests in blood bank screening. Transfusion. 1993;33:830–4.
150. Pastini AC, Iglesias SR, Carricante VC, Guerin ME, Sánchez D, Frasch
AC. Immunoassay with recombinant Trypanosoma cruzi antigens
potentially useful for screening donated blood and diagnosing
Chagas disease. Clin Chem. 1994;40:1893–7.
151. Peralta JM, Teixeira‑MGM, Shreffler WG, Pereira JB, Burns JM,
Steath PR, et al. Serodiagnosis of Chagas' disease by enzyme-linked
immunosorbet assay using two synthetic peptides as antigens. J
Clin Microbiol. 1994;32:971–4.
152. Granjon E, Dichtel‑Danjoy M‑L, Saba E, Sabino E, Campos de Oliveira
L, Zrein M. Development of a novel multiplex immunoassay multi‑
crului for the serological confirmation of Chagas disease. PLoS Negl
Trop Dis. 2016;10:e0004596.
153. Houghton RL, Benson DR, Reynolds L, McNeill P, Steath P, Lodes M,
et al. Multi‑epitope synthetic peptide and recombinant protein for the
detection of antibodies to Trypanosoma cruzi in patients with treated
or untreated Chagas' disease. J Infect Dis. 2000;181:325–30.
154. Hernández P, Heimann M, Riera C, Solano M, Santalla J, Luquetti AO,
et al. Regional variation in the correlation of antibody and T‑cell
responses to Trypanosoma cruzi II/V/VI reservoir hosts among
South American countries. PLoS ONE. 2019;14:e0215623.
155. Santos FLN, Celenon PA, Zanchin NI, Souza WV, Silva ED, Foti L,
et al. Accuracy of chimeric proteins in the serological diagnosis
of chronic Chagas disease—a Phase II study. PLoS Negl Trop Dis.
2017;11:e0005433.
156. Dopedo E, Del‑Rei RP, Espinoza B, Ulibarri I, Zanchin NI, Sulleiro E,
et al. Immune reactivity to Trypanosoma cruzi chimeric proteins for
Chagas disease diagnosis in immigrants living in a non‑endemic set‑
ing. BMC Infect Dis. 2019;19:251.
157. Del‑Rei RP, Leony LM, Celenon PAF, Zanchin NI, Reis MG, Gomes
YDM, et al. Detection of anti‑Trypanosoma cruzi antibodies by chimer‑
ic antigens in chronic Chagas disease‑individuals from endemic
South American countries. PLoS ONE. 2019;14:e0215623.
158. Santos FLN, Campos ACP, Amorim LDAF, Silva ED, Zanchin NI, Cel‑
don PAF, et al. Highly accurate chimeric proteins for the serological
diagnosis of chronic Chagas disease: a latent class analysis. Am J Trop
Med Hyg. 2018;99:1174–9.
159. Daltro RT, Leony LM, Freitas NEM, Silva ÂAO, Santos EF, Del‑Rei RP,
et al. Cross‑reactivity using chimeric Trypanosoma cruzi antigens: diagnostic performance in settings co‑endemic for Chagas disease
and American cutaneous or visceral leishmaniasis. J Clin Microbiol.
2019. https://doi.org/10.1128/JCM.00762‑19.
180. Alvarez M, Cerisola J, Rohwedde R. Test de inmunofluorescencia para el diagnóstico de la enfermedad de Chagas. Bol Chil Parasitol. 1968;23:4–9.

181. Lauricella M, Castañera M, Gürtler R, Segura E. Immunodiagnosis of *Trypanosoma cruzi* (Chagas’ disease) infection in naturally infected dogs. Mem Inst Oswaldo Cruz. 1998;93:501–7.

182. Rodríguez-Morales O, Ballinas-Verdugo MA, Alejandro-Aguilar R, Reyes PA, Arce-Fonseca M. *Trypanosoma cruzi* connatal transmission in dogs with Chagas disease: experimental case report. Vector Borne Zoonotic Dis. 2011;11:1365–70.

183. Lauricella MA, Wisnivesky-Colli C, Gürtler R, Petersen R, Bujas M, Segura EL. Standardization of serological tests for detecting anti-*Trypanosoma cruzi* antibodies in dogs. Mem Inst Oswaldo Cruz. 1993;88:413–7.

184. Lauricella M, AR R, JO L, A B, EL S. Enfermedad de Chagas en perros experimentalmente infectados con *T. cruzi*. Medicina. 1986;46:195–200.

185. Sartor PA, Cardinal MV, Orozco MM, Gürtler RE, Leguizamón MS. Trans-sialidase neutralizing antibody detection in *Trypanosoma cruzi*-infected domestic reservoirs. Clin Vaccine Immunol. 2011;18:984–9.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.